ubmslateEN-logo-ubm

EN Mobile Logo

Search form

Topics:

GLP-1

GLP-1 Receptor Agonists vs Other Anti-Diabetics

A network meta-analysis compared GLP-1 receptor agonists to traditional anti-diabetes drugs based on hypoglycemia incidence, HbA1c goals, and more.

 

© Kim Reinick/Shutterstock.com

GLP-1

Do low-risk CVD patients with T2DM experience the same significantly lower all-cause and CV mortality seen in high-risk patients?

Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.

Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.

The Qatar Study investigated the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in poorly-controlled type 2 diabetes.

Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.

How do you treat patients with type 2 diabetes unable to achieve glycemic control with either oral treatment or basal insulin?

SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.

Pages

Subscribe to GLP-1 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.